Provided by Tiger Fintech (Singapore) Pte. Ltd.

BriaCell Therapeutics Corp.

0.7400
+0.00100.14%
Post-market: 0.7200-0.0200-2.70%19:57 EDT
Volume:462.56K
Turnover:340.11K
Market Cap:13.89M
PE:-0.11
High:0.7449
Open:0.7400
Low:0.7200
Close:0.7390
52wk High:29.40
52wk Low:0.6100
Shares:18.78M
Float Shares:16.23M
Volume Ratio:0.70
T/O Rate:2.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.9195
EPS(LYR):-4.3678
ROE:-688.17%
ROA:-131.54%
PB:1.12
PE(LYR):-0.17

Loading ...

Company Profile

Company Name:
BriaCell Therapeutics Corp.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
16
Office Location:
Bellevue Centre,Suite 300,235 -15th Street,West Vancouver,British Columbia,Canada
Zip Code:
V7T 2X1
Fax:
604-921-1898
Introduction:
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Directors

Name
Position
Jamieson Bondarenko
Chairman of the Board
William V. Williams
President, Chief Executive Officer and Director
Jane A. Gross
Director
Marc Lustig
Director
Martin E. Schmieg
Director
Rebecca Taub
Director
Vaughn C. Embro Pantalony
Director

Shareholders

Name
Position
William V. Williams
President, Chief Executive Officer and Director
Gadi Levin
Chief Financial Officer and Corporate Secretary
Giuseppe Del Priore
Chief Medical Officer
Miguel A. Lopez Lago
Chief Scientific Officer